Intratumoral CD8+ T lymphocytes as a prognostic factor of survival in endometrial carcinoma

Clinical Cancer Research

Volumn 10, Issue 13, 2004, Pages 4450-4456

  Kondratiev, Svetlana ^a   Sabo, Edmond ^a   Yakirevich, Evgeny ^a   Lavie, Ofer ^a   Resnick, Murray B ^a  

^a CARMEL MEDICAL CENTER   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

CD8 ANTIGEN; GRANZYME B;

AGED; ARTICLE; CANCER GRADING; CANCER STAGING; CANCER SURVIVAL; ENDOMETRIOID CARCINOMA; ENDOMETRIUM CARCINOMA; FEMALE; FEMALE GENITAL TRACT CANCER; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROGNOSIS; T LYMPHOCYTE;

ANTIGENS, CD8; CARCINOMA, ENDOMETRIOID; CARCINOMA, PAPILLARY; CD8-POSITIVE T-LYMPHOCYTES; CELL SURVIVAL; CYTOPLASM; ENDOMETRIAL NEOPLASMS; FEMALE; GRANZYMES; HUMANS; IMMUNOHISTOCHEMISTRY; MULTIVARIATE ANALYSIS; PROGNOSIS; RISK FACTORS; SERINE ENDOPEPTIDASES; T-LYMPHOCYTES; TIME FACTORS; TREATMENT OUTCOME;

EID: 3042733614     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-0732-3     Document Type: Article

References (34)

1. Landis SH, Murray T, Bolden S, Wingo PA. Cancer statistics. CA Cancer J Clin 1998;48:6.
2. Ambros RA, Kurman RJ. Combined assessment of vascular invasion and myometrial invasion as a model to predict prognosis in stage I endometrioid adenocarcinoma of uterine corpus. Cancer (Phila) 1992;69:1424-31.
3. Zaino RJ, Kurman RJ, Diana KL, Morrow CP. Pathologic models to predict outcome for women with endometrial adenocarcinoma. Cancer (Phila) 1996;77:1115-21.
4. Ambros RA, Kurman RJ. Identification of patients with stage I uterine endometrioid adenocarcinoma at high risk of recurrence by DNA ploidy, myometrial invasion, and vascular invasion. Gynecol Oncol 1992;45:235-9.
5. Yoshiki I, Koshiro O, Kunio A, et al. The prognostic significance of vascular invasion by endometrial carcinoma. Cancer (Phila) 1996;78:1447-51.
6. Gehrig PA, Linda Van Le, Olatidoye B, Geradts J. Estrogen receptor status, determined by immunohistochemistry, as a predictor of the recurrence of stage I endometrial carcinoma. Cancer (Phila) 1999;86:2083-9.
7. Fine BA, Valente PT, Feinstein GI, Dey T. VEGF, flt-1, and KDR/flk-1 as prognostic indicators in endometrial carcinoma. Gynecol Oncol 2000;76:33-9.
8. McCluggage WG, Maxwell P, Hamilton PW, Jasani B. High metallothionein expression is associated with features predictive of aggressive behaviour in endometrial carcinoma. Histopathology 1999;34:51-5.
9. Fanning J, Brown S, Phibbs G, Kramer T, Zaher A. Immunohistochemical evaluation is not prognostic for recurrence in fully staged high-risk endometrial cancer. Int J Gynecol Cancer 2002;12:286-9.
10. Bell JG, Minnick A, Reid GC, Judis J, Brownell M. Relationship of nonstaging pathological risk factors to lymph node metastasis and recurrence in clinical stage I endometrial carcinoma. Gynecol Oncol 1997;66:388-92.
11. Ferguson A, Moore M, Fox H. Expression of MHC products and leukocyte differentiation antigens in gynaecological neoplasms: an immunohistological analysis of the tumor cells and infiltrating leukocytes. Br J Cancer 1995;52:551-63.
12. + T cells infiltrated within cancer cell nests as a prognostic factor in human colorectal cancer. Cancer Res 1998;58:3491-4.
13. Saiki Y, Ohtani H, Naito Y, Miyazawa M, Nagura H. Immunophenotypic characterisation of EBV-associated gastric carcinoma: massive infiltration by proliferating CD8+ lymphocytes. Lab Investig 1996;75:67-76.
14. Bontkes HJ, Walboomers JMM, Gunter AW, et al. Assessment of cytotoxic T-lymphocyte phenotype using the specific markers granzyme B and TIA-1 in cervical neoplastic lesions. Br J Cancer 1997;76:1353-60.
15. Yakirevich E, Ben Izhak O, Rennert G, Kovacs ZG, Resnick MB. Cytotoxic phenotype of tumor infiltrating lymphocytes in medullary carcinoma of the breast. Mod Pathol 1999;12:1050-6.
16. Yakirevich E, Lefel O, Sova Y, et al. Activated status of tumour-infiltrating lymphocytes and apoptosis in testicular seminoma. J Pathol 2002;196:67-75.
17. + T cells infiltrations within esophageal carcinomas. Cancer Res 2001;61:3932-6.
18. + T lymphocytes as a prognostic factor in human renal cell carcinoma. Cancer Res 2001;61:5132-6.
19. Anonymous. Announcements: FIGO stages-1988 revision. Gynecol Oncol 1989;35:125-7.
20. Creasman W. New gynecologic cancer staging. Obstet Gynecol 1990;75:287-8.
21. Clark WH, Elder DE, Guerry DP, et al. Model predicting survival in stage I melanoma based on tumor progression. J Natl Cancer Inst (Bethesda) 1989;81:1893-904.
22. Zhang L, Conejo-Garcia JR, Katsaros D, et al. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med 2003;348:203-13.
23. Pui CH, Ip SH, Dodge RK, et al. Serum levels of CD 8 antigen in childhood lymphoid malignancies: a possible indicator of increased suppressor cell activity in poor-risk patient. Blood 1988;73:1015-21.
24. Oudejans JJ, Jiwa NM, Kummer JA, et al. Activated cytotoxic T cells as prognostic marker in Hodgkin's disease. Blood 1997;89:1376-82.
25. Yamazawa K, Seki K, Matsui H, Sekiya S. Significance of perivascular lymphocyte infiltrates in endometrial carcinoma. Cancer (Phila) 2001;91:1777-84.
26. Lee KR, Vacek PM, Belinson JL. Traditional and nontraditional histopathologic predictors of recurrence in uterine endometrioid carcinoma. Gynecol Oncol 1994;54:10-8.
27. Silverberg SG, Sasano N, Yajima A. Endometrial carcinoma in Miyagi prefecture, Japan: histopathological analysis of cancer registry-based series and comparison with cases in American women. Cancer (Phila) 1982;449:1504-10.
28. Deligdisch L. Morphologic correlates of host response in endometrial arcinoma. Am J Reprod Immunol 1982;2:54-7.
29. Germain RN, Margulies DM. The biochemistry and cell biology of antigen processing and presentation. Annu Rev Immunol 1993;11:403-50.
30. Boon T, Old LJ. Cancer tumor antigens. Curr Opin Immunol 1997;9:681-3.
31. Van Der Eynde BJ, Van Der Bruggen P. T cells defined tumor antigens. Curr Opin Immunol 1997;9:684-93.
32. Van Der Bruggen P, Traversari C, Knuth T, Boon A. A gene encoding an antigen recognized by cytotoxic T lymphocytes on a human melanoma. Science (Wash DC) 1991;254:1643-7.
33. Resnick MB, Sabo E, Kondratiev S, Kerner H, Spagnoli GC, Yakirevich E. Cancer-testis antigen expression in uterine malignancies with an emphasis on carcinosarcomas and papillary serous carcinomas. Int J Cancer 2002;101:190-5.
34. Kummer JA, Kamp AM, Tadema TM, Vos W, Meijer CJLM, Mack CE. Localization and identification of granzyme A and B-expressing in normal human lymphoid tissue and peripheral blood. Clin Exp Immunol 1995;100:164-72.